Press Releases

28 September 2023
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
18 September 2023
BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission
11 September 2023
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
30 August 2023
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
14 August 2023
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
7 August 2023
BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
31 July 2023
BioNTech Completes Acquisition of InstaDeep
24 July 2023
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
29 June 2023
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
23 June 2023
Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. BioNTech disavows any obligation to update the information contained in such press releases after the date of their issuance.